IRVINE, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today it has appointed Dr. Matthew Roberts, Ph.D. to the Company’s Scientific Advisory Board (“SAB”).
Dr. Roberts is an accomplished innovation executive with over 25 years of success at the industry’s major companies. Currently he is managing, growing and advising startup companies across the food, nutrition, and digital health industries. Dr. Roberts will add further operational, development, and discovery experience to the SAB.
He has achieved outstanding results in both the commercial and research sides of business, leading to successful introduction of hundreds of new food products, ingredients, and science & technology resulting in material improvements in business performance. He has launched concentrated, sterile, and clear protein beverages that have grown both share and margin on major human nutrition brands in both retail and healthcare institutions. His work has also contributed to advances in infant nutrition and care. In the companion animal sector, his work has shaped veterinary and retail animal diets with new approaches to improving the lives of pets. Through his business development work, he has participated or led acquisitions and equity investments, which have resulted in significant structural shifts in the human and companion animal nutrition industry. Operationally, he has worked with global supply chains, procurement, pilot production scale up of innovations, stage gate evaluations, and development of strategic corporate partnerships.
As a scientist, Dr. Roberts managed a variety of teams and projects with significant annual budgetary responsibilities. He is the author or editor of numerous peer-reviewed scientific publications, professional publications, and patents. He has presented at hundreds of international life and food science conferences over his career. He has mentored Ph.D. students as an industrial advisor and thesis committee member as well as taught graduate level courses at the ETH and EPFL (Switzerland).
About the ChromaDex SAB:
The ChromaDex SAB is chaired by Roger Kornberg, a Professor at Stanford Medical School, who was awarded the Nobel Prize in Chemistry in 2006 for his research on the molecular basis of eukaryotic transcription. Dr. Kornberg earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an Assistant Professor of Biological Chemistry at Harvard Medical School in 1976, before moving to his present position as Professor of Structural Biology at Stanford Medical School in 1978.
Kornberg’s father, the late Arthur Kornberg, was a professor of biochemistry at Stanford and was awarded the Nobel Prize for Physiology or Medicine in 1959. He was among the first to investigate nicotinamide riboside more than 60 years ago while at the National Institute of Health (NIH).
The SAB’s mission is to assist the Company’s management team in maximizing the value of the Company’s portfolio of patented ingredients by advising on such matters as scientific and research focus, clinical studies, safety and regulatory, commercialization opportunities, and assessing new potential ingredient technologies.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended., Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Public Relations Contact: Breah Ostendorf, Director of Marketing 949-537-4103 firstname.lastname@example.org ChromaDex Investor Relations Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 email@example.com